Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic advances in ADPKD: the future awaits
Ivana Capuano, Pasquale Buonanno, Eleonora Riccio, et al.
Journal of Nephrology (2021) Vol. 35, Iss. 2, pp. 397-415
Closed Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Exome Sequencing of a Clinical Population for Autosomal Dominant Polycystic Kidney Disease
Alex R. Chang, Bryn S. Moore, Jonathan Z. Luo, et al.
JAMA (2022) Vol. 328, Iss. 24, pp. 2412-2412
Open Access | Times Cited: 54
A miRNA-Based Approach in Autosomal Dominant Polycystic Kidney Disease: Challenges and Insights from Adult to Pediatric Evidence
Caterina Vitulano, Gabriele Forcina, Simone Colosimo, et al.
Molecular Diagnosis & Therapy (2025)
Closed Access
Targeting TRPM3 as a potential therapeutic approach for autosomal dominant polycystic kidney disease
Hüseyin Gül, Jamie A. Davies
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Autosomal Dominant Polycystic Kidney Disease-Related Multifocal Renal Cell Carcinoma: A Narrative Iconographic Review
Consolato Sergi, Luis Guerra, Josef Häger
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 9, pp. 3965-3965
Open Access
Molecular Mechanisms of Epigenetic Regulation, Inflammation, and Cell Death in ADPKD
Ewud Agborbesong, Xiaoyan Li, Lu Li, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 18
Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights
Irene Capelli, Sarah Lerario, Francesca Ciurli, et al.
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 5, pp. 469-484
Closed Access | Times Cited: 2
Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Kitty St Pierre, Brydee Cashmore, Davide Bolignano, et al.
Cochrane library (2024) Vol. 2024, Iss. 10
Closed Access | Times Cited: 2
Recent findings on the role of microRNAs in genetic kidney diseases
Hassan Askari, Ehsan Raeis-Abdollahi, Mohammad Foad Abazari, et al.
Molecular Biology Reports (2022) Vol. 49, Iss. 7, pp. 7039-7056
Closed Access | Times Cited: 11
Parapelvic Cysts: An Imaging Marker of Kidney Disease Potentially Leading to the Diagnosis of Treatable Rare Genetic Disorders? A Narrative Review of the Literature
Ivana Capuano, Pasquale Buonanno, Eleonora Riccio, et al.
Journal of Nephrology (2022) Vol. 35, Iss. 8, pp. 2035-2046
Closed Access | Times Cited: 10
Metabolism-based approaches for autosomal dominant polycystic kidney disease
Ivona Bakaj, Alessandro Pocai
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 5
Molecular Diagnosis and Identification of Novel Pathogenic Variants in a Large Cohort of Italian Patients Affected by Polycystic Kidney Diseases
Ersilia Nigro, Maria Amicone, Daniela D’Arco, et al.
Genes (2023) Vol. 14, Iss. 6, pp. 1236-1236
Open Access | Times Cited: 4
Multidisciplinary management improves the genetic diagnosis of hereditary kidney diseases in the next generation sequencing (NGS) era
Isabel Galán, Liliana Galbis Martínez, Víctor Martínez, et al.
Nefrología (English Edition) (2024) Vol. 44, Iss. 1, pp. 69-76
Open Access | Times Cited: 1
Comparative Efficacy of Pharmacological Treatments for Adults With Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Shunichiro Tsukamoto, Shingo Urate, Takayuki Yamada, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 6
Assessment of Cardiovascular Disease in Autosomal Dominant Polycystic Kidney Disease
Antonietta Gigante, Adolfo Marco Perrotta, Francesca Tinti, et al.
Applied Sciences (2023) Vol. 13, Iss. 12, pp. 7175-7175
Open Access | Times Cited: 3
Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease
Shubhangi Saxena, Neha Dagar, Vishwadeep Shelke, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 11, pp. 103765-103765
Closed Access | Times Cited: 2
Restoration of atypical protein kinase C ζ function in autosomal dominant polycystic kidney disease ameliorates disease progression
Masaw Akbari, Jonathan West, Nicholas Doerr, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 30
Open Access | Times Cited: 4
Compassionate use of tolvaptan in acquired megacolon secondary to autosomal dominant polycystic kidney disease (ADPKD)
Iris Viejo-Boyano, Paul José Hernández Velasco, Eduardo Gutiérrez Martínez
Nefrología (English Edition) (2024) Vol. 44, Iss. 2, pp. 301-303
Open Access
Introductory Chapter: Chronic Kidney Disease – Introductive Overview and Current Issues
Giovanni Palleschi
IntechOpen eBooks (2024)
Closed Access
MQ232, A Snake Toxin Derivative for Treatment of Hyponatremia and Polycystic Kidney Diseases
Goran Stanajic‐Petrovic, Mathilde Keck, Peggy Barbe, et al.
Journal of the American Society of Nephrology (2024)
Closed Access
Functional impairments, known genetic disorders, and review reports of established and possible therapies for specific genetic diseases
Moyra Smith
Elsevier eBooks (2024), pp. 159-205
Closed Access
Tolvaptan Safety in Autosomal Dominant Polycystic Kidney Disease; Focus on Idiosyncratic Drug Induced Liver Injury Liabilities
Sean Hammond, Xiaoli Meng, Jane Barber, et al.
Toxicological Sciences (2024)
Open Access
Phosphoproteomic response to epidermal growth factor in native rat inner medullary collecting duct
Chung‐Lin Chou, Nipun U. Jayatissa, Elena T Kichula, et al.
AJP Renal Physiology (2024) Vol. 328, Iss. 1, pp. F29-F47
Closed Access
Efek Terapeutik Analog Somatostatin dalam Menghambat Perkembangan Autosomal Dominant Polycystic Kidney Disease

Jurnal Penyakit Dalam Indonesia (2024) Vol. 11, Iss. 4
Open Access
Activation of tolvaptan-responsive T-cell clones with the structurally-related mozavaptan
Sean Hammond, Xiaoli Meng, Merrie Mosedale, et al.
Toxicology Letters (2022) Vol. 373, pp. 148-151
Open Access | Times Cited: 1
Was ist gesichert in der Therapie der autosomal-dominanten polyzystischen Nierenerkrankung?
Vera Christine Wulfmeyer, Roland Schmitt
Der Internist (2021) Vol. 62, Iss. 12, pp. 1259-1268
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top